Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Suven Life Sciences Ltd (SUVEN)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530239 NSE: SUVEN Pharmaceuticals & Drugs | Small Cap | Suven Life Sciences Share Price
₹330.10 -9.95 (-2.93%)
As on 12-Aug'26 16:59
Suven Life Sciences Ltd (SUVEN)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530239 NSE: SUVEN Pharmaceuticals & Drugs | Small Cap | Suven Life Sciences Share Price
₹330.10 -9.95 (-2.93%)
As on 12-Aug'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹9,609 Cr.
Current Price
₹330.1
52-Week Low / High
₹124 / 371
TTM EPS
₹-2
TTM Sales
₹8.8 Cr.
Book Value per Share
₹55.9
P/E Ratio
0.00
Industry PE
53.8
Price to Book (P/B)
6.08
Higher than its 5-year historical median
Price to Sales (P/S)
1090.15
Higher than its 5-year historical median
EV/EBITDA
-188.68
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
-5.12%
Underperforms industry median
Return on Capital Employed (ROCE)
-4.74%
Underperforms industry median
Return on Assets (ROA)
-4.69%
Operating Profit Margin
-880.7%
Net Profit Margin
-771.12%
Gross Profit Margin
-692.2%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
6.76%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
70.08%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹1,552 Cr.
Equity
₹28.3 Cr.
Face Value
₹1
All Time Low / High
₹0.55 / 371.00
Check Before You Invest
Quality
Not GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Strong
Is Suven Life Sciences Ltd a good quality company?
Suven Life Sciences Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Suven Life Sciences Ltd performance compare with that of its Peers?
Revenue growth of Suven Life Sciences Ltd vs industry peers?
Suven Life Sciences Ltd revenue CAGR is -12.01%, compared to the industry median CAGR of 5.68%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Suven Life Sciences Ltd?
Promoters hold 70.08% of the Suven Life Sciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Suven Life Sciences Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 5.9% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Suven Life Sciences Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 21.9% | 27.6% | 10% | -6.4% | -6.8% | -8.1% | -3% | -1% | -5.7% | -4.7% | - |
| Value Creation Index ⓘ | 0.6 | 1.0 | -0.3 | -1.5 | -1.5 | -1.6 | -1.2 | -1.1 | -1.4 | -1.3 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 544 | 625 | 286 | 14.4 | 13.5 | 11.8 | 13.5 | 11.7 | 6.7 | 7.1 | 9 |
| Sales YoY Gr. | - | 15% | -54.3% | -95% | -6.5% | -12.2% | 14.4% | -13.7% | -43% | 6.8% | - |
| Adj EPS ⓘ | 8 | 10.4 | 1.5 | -1 | -1.6 | -2.5 | -1.2 | -0.8 | -2.3 | -2.3 | -2 |
| YoY Gr. | - | 29.7% | -85.2% | -166% | NA | NA | NA | NA | NA | NA | - |
| BVPS (₹) ⓘ | 53 | 62.8 | 29.1 | 28.1 | 26.4 | 30.2 | 39.1 | 38.8 | 36.6 | 51 | 55.9 |
| Adj Net Profit ⓘ | 110 | 143 | 21.2 | -14 | -22.4 | -38.8 | -25.4 | -16.4 | -50.4 | -61.4 | -56 |
| Cash Flow from Ops. ⓘ | 147 | 105 | -12 | -45.2 | -36.7 | -36.6 | -22.9 | -20.6 | -47.4 | -69.2 | - |
| Debt/CF from Ops. ⓘ | 0.5 | 0.3 | -0.2 | -0 | -0 | -0 | 0 | 0 | 0 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -38.2% | -12% | -19.3% | 6.8% | ||||
| Adj EPS ⓘ | -187.2% | NA | NA | NA | ||||
| BVPSⓘ | -0.4% | 14.1% | 9.3% | 39.5% | ||||
| Share Price | 6% | 34.1% | 71.2% | 39.9% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 16.3 | 17.9 | 3.3 | -3.5 | -5.7 | -8.8 | -3.8 | -1.9 | -6.1 | -5.3 | -3.7 |
| Op. Profit Mgn % ⓘ | 30.6 | 37.3 | 17.1 | -243.3 | -222.9 | -304.6 | -201.7 | -263.3 | -775.4 | -880.7 | -794.4 |
| Net Profit Mgn % ⓘ | 20.3 | 22.9 | 7.4 | -96.9 | -166.1 | -327.4 | -187.2 | -139.9 | -757.3 | -862.6 | -638.3 |
| Debt to Equity ⓘ | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 191 | 193 | 357 | 5,193 | 5,219 | 4,006 | 4,382 | 3,617 | 886 | 1,155 | 14,606 |
| Cash Conv. Cycle ⓘ | 56 | 57 | 81 | 12 | 21 | 31 | 13 | 29 | 75 | 51 | 13,980 |
Valuation of Suven Life Sciences - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 544 | 625 | 286 | 14 | 13 | 12 | 14 | 12 | 7 | 7 |
| Operating Expenses ⓘ + | 378 | 392 | 237 | 50 | 44 | 48 | 41 | 43 | 58 | 70 |
| Operating Profit ⓘ | 165 | 233 | 49 | -35 | -30 | -37 | -28 | -31 | -52 | -63 |
| Operating Profit Margin (%) | 30.4% | 37.3% | 17.0% | -244.0% | -225.0% | -308.0% | -204.0% | -263.0% | -778.0% | -884.0% |
| Other Income ⓘ + | 21 | 23 | 27 | 14 | 8 | 2 | 8 | 21 | 11 | 14 |
| Interest ⓘ | 6 | 5 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Depreciation ⓘ | 21 | 21 | 11 | 4 | 4 | 4 | 7 | 7 | 6 | 6 |
| Profit Before Tax ⓘ | 159 | 230 | 63 | -26 | -28 | -36 | -20 | -9 | -47 | -55 |
| Tax ⓘ | 36 | 72 | 24 | -12 | -5 | 0 | 0 | -1 | 0 | 0 |
| Profit After Tax | 123 | 158 | 39 | -14 | -23 | -36 | -20 | -8 | -47 | -55 |
| PAT Margin (%) | 22.7% | 25.3% | 13.7% | -95.4% | -167.0% | -306.0% | -148.0% | -68.5% | -707.0% | -771.0% |
| Adjusted EPS (₹) | 8.9 | 11.5 | 2.8 | -1.0 | -1.6 | -2.3 | -0.9 | -0.4 | -2.2 | -2.1 |
| Dividend Payout Ratio (%) | 10.30% | 12.10% | 48.70% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 732 | 867 | 402 | 388 | 365 | 476 | 853 | 845 | 798 | 1,346 | |
| Debt + | 56 | 33 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 38 | 57 | 7 | 6 | 3 | 2 | 2 | 2 | 5 | 5 | |
| Others Liabilities ⓘ | 138 | 162 | 146 | 109 | 141 | 102 | 99 | 4 | 5 | 180 | |
| Total Liabilities ⓘ | 964 | 1,119 | 557 | 503 | 509 | 580 | 954 | 851 | 809 | 1,531 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 306 | 308 | 22 | 25 | 21 | 38 | 37 | 28 | 60 | 73 | |
| CWIP ⓘ | 10 | 25 | 0 | 0 | 5 | 4 | 0 | 0 | 0 | 4 | |
| Investments ⓘ | 366 | 381 | 359 | 242 | 295 | 426 | 528 | 653 | 714 | 1,093 | |
| Inventories | 93 | 139 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
| Trade Receivables | 46 | 62 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | |
| Cash Equivalents | 5 | 21 | 0 | 1 | 39 | 3 | 174 | 153 | 20 | 331 | |
| Others Assets ⓘ | 139 | 183 | 172 | 233 | 148 | 109 | 214 | 15 | 14 | 28 | |
| Total Assets ⓘ | 964 | 1,119 | 557 | 503 | 509 | 580 | 954 | 851 | 809 | 1,531 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 147 | 105 | -12 | -45 | -37 | -37 | -23 | -21 | -47 | -69 |
| Cash Flow From Investing Activity ⓘ + | -353 | -38 | 3 | 42 | 2 | -107 | -349 | -1 | 44 | -686 |
| Cash Flow From Financing Activity ⓘ + | -30 | -52 | 5 | 4 | 35 | 146 | 396 | -1 | -1 | 757 |
| Net Cash Flow ⓘ | -236 | 15 | -4 | 1 | 1 | 2 | 24 | -22 | -4 | 2 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 18.22 | 19.83 | 6.18 | -3.48 | -6.02 | -8.62 | -3.03 | -0.94 | -5.73 | -5.12 |
| ROCE (%) | 21.88 | 27.58 | 9.98 | -6.4 | -6.82 | -8.1 | -2.97 | -1.03 | -5.71 | -4.74 |
| Asset Turnover Ratio | 0.59 | 0.6 | 0.34 | 0.03 | 0.03 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
| PAT to CFO Conversion(x) | 1.2 | 0.66 | -0.31 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Working Capital Days | ||||||||||
| Receivable Days | 33.30 | 31.30 | 41 | 62.20 | 54.60 | 47.20 | 28.40 | 32.70 | 71.90 | 73 |
| Inventory Days | 59 | 67.70 | 0 | 0 | 3.80 | 2.50 | 0 | 22.10 | 25.90 | 8.70 |
| Payable Days | 91.30 | 113.60 | 169.70 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Suven Life Sciences Ltd FAQs
The current trading price of Suven Life Sciences on 12-Aug-2026 16:59 is ₹330.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 11-Aug-2026 the market cap of Suven Life Sciences stood at ₹9,608.5 Cr
The latest P/E ratio of Suven Life Sciences as of 11-Aug-2026 is 0.00.
The latest P/B ratio of Suven Life Sciences as of 11-Aug-2026 is 6.08.
The 52-week high of Suven Life Sciences is ₹371.0 and the 52-week low is ₹124.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Suven Life Sciences is ₹8.81 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Suven Life Sciences Ltd is a below average quality company.
The key valuation ratios of Suven Life Sciences Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Suven Life Sciences Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Suven Life Sciences Ltd
Suven Life Sciences was promoted by Mrs. and Mr. Venkat Jasti in 1989, as a Private Limited Company. Later it was converted into a Public Limited Company in January 1995.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.
Shares are listed at Bombay Stock Exchange (BSE), National Stock Exchange (NSE), and Hyderabad Stock Exchange(HSE). It has a state of the art R&D center recognized by Department of Scientific & Industrial Research (DSIR), Ministry of Science and Technology, Government of India. Also, it has world class manufacturing facilities in the business of Pharmaceuticals and Fine Chemical Intermediates for Global Life Science Companies for New Chemical Entities (NCE's).
Business Units
C.R.A.M.S
The company’s main thrust is in Contract Research and Manufacturing Services (C-R-A-M-S). Suven's ‘C-R-A-M-S’ is in existence since 1991 serving as many as 22 global Life Science and Fine Chemical Companies by developing and supplying cost effective Pharmaceutical and Agro Chemical Intermediates for New Chemical Entities (NCE's) meeting world standards of Quality, Speed and Respect for Environment.
DDDSS
Drug Discovery & Development Support Services (DDDSS) aims to provide Contract Drug Discovery & Development services in Medicinal chemistry, Process chemistry, Analytical chemistry, In-vitroScreening, DMPK, Brain Microdialysis, CV Safety, In-vivo Metabolic Disorders & CNS Pharmacology, Phase-I Bio-analysis and Discovery Toxicology.
Suven Nishtaa Pharma
Suven Nishtaa Pharma (Suven Nishtaa), a joint venture company of Suven Life Sciences, is a Pharmaceutical Formulations Contract Services provider.
Suven Nishtaa, a 100% Export Oriented Unit, is engaged in providing end-to-end Drug Product Development services, viz.
Products
- Advanced Intermediates
- IntermediatesActive
- Pharmaceutical Ingredients (APIs )
- Stock Chemicals for Disposal
Milestones
- 1989 Incorporation as Suven Pharmaceuticals Pvt. Ltd.
- 1990 Commenced Operations
- 1991 Expanded into Fine Chemical Intermediates
- 1992 Commenced export of Fine Chemical Intermediates
- 1994 Initiation of 'C-R-A-M-S' business model (Contract Research And Manufacturing Services)
- 1995 Went Public (IPO)
- 1996 First sale from 'C-R-A-M-S'
- 1997 ISO 9002 Certification
- 1999 Recognition as an Export House
- 1999 Acquired a Drug Unit at Hyderabad, converted into Research center and Pilot Plant
- 2001 New Suven Research Center (SRC) inaugurated at Hyderabad
- 2001 Recognition of SRC as in-house R & D unit by Department of Scientific & Industrial Research (DSIR), India
- 2001 Borregaard takes equity stake
- 2002 cGMP Lab at SRC commissioned
- 2003 Acquired assets of New Jersey, USA based Synthon Chiragenics Corporation
- 2003 Name changed to Suven Life Sciences Limited
- 2004 Gets ISO 14001:1996 certification for Unit - 1 (Suryapet) and Unit - 2 (Jeedimetla)
- 2005 Suven Awarded 2005 - Partner of Choice in Drug Discovery for CNS by Frost & Sullivan
- 2005 Suven Awarded Phase III Clinical study for Chronic Low Back pain.
- 2006 Suven receives National Accreditation Board for Testing and Calibration Laboratories (NABL) certification
- 2006 Suven and Lilly Establish Drug Discovery Collaboration
- 2006 Amalgamation of ASIAN CLINICAL TRIALS ( ACT)
- 2006 All the units got Certification for ISO 9001 , ISO 14001, OHSAS 18001
- 2007 Suven Unit III cGMP facility accepted by USFDA for manufacture of API's
- 2007 Suven enters into collaboration with University of Minnesota to develop drugs to treat HIV infection
- 2007 Suven Life Sciences secures two Product Patents in Australia & New Zealand for their New Chemical Entities (NCEs)
- 2007 Suven Life Sciences secures two Product Patents from European Patent Office (EPO) for the treatment of Neurodegenerative diseases.
- 2007 Suven obtains 1st Product Patent from US Patent office
- 2008 Suven obtains 2nd Product Patent from US Patent office
- 2008 Suven Establishes second CNS Drug Discovery Collaboration with Lilly
- 2008 Suven Life Sciences secures Two product Patents in all Russian countries (Eurasia Region)
- 2008 Suven Life Sciences gets Two Product patents in Korea and Mexico
- 2008 Suven Life Sciences ACT Enters into an Alliance with VPSCRO
- 2008 Suven Life Sciences gets Two product patents for NCEs in South Africa and China
- 2008 Suven granted Certificate of Suitability (CEP) for Tamsulosin Hydrochloride
- 2009 US FDA ACCEPTANCE to UNIT- I, Suryapet
- 2010
Suven Secures Two product patents in China and Russia
Suven Life Sciences secures 5th Product Patent from US patent office for their NCE to treat Central Nervous System
Suven Life Sciences bagged the eight product patent from European Patent Office (EPO) for their NCE to treat Central Nervous System (CNS) disorders.
Suven Life Secures Three Australian Patents on NCEs
Suven gets two patents from Japanese Patent Office for NCE's - 2011
Suven's Unit-III receives US FDA Acceptance
Suven Life Sciences secures 7 Product Patents for their NCEs in several key markets in the world
Suven Life Sciences bags ""Bio-Excellence Award at Bangalore India Bio 2011
Suven Life Sciences secures 2 Product Patents for their NCEs in the key markets in the world
Suven Life Sciences bags Pharmexcil's Gold ""Patent Award"" - 2012
Suven Life Sciences secures 3 Product Patents for their NCEs in Mexico and USA
Suven Life Sciences gets 4 Product Patents in Japan, Australia, Europe and Eurasia
Suven Life Sciences bags Pharmexcil's ""Platinum Patent Award""
Suven Life Sciences secures 5 Product Patents for their NCEs in China & Korea.
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
